Page last updated: 2024-11-13

meclocycline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID54676539
CHEMBL ID1237124
CHEBI ID135772
SCHEMBL ID3445
SCHEMBL ID1650332
SCHEMBL ID12841672
SCHEMBL ID23247761
MeSH IDM0262717

Synonyms (47)

Synonym
7-chloro-6-methylene-5-oxytetracycline
2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4s-(4alpha,4aalpha,5alpha,5aalpha,12aalpha))-
nsc 78502
einecs 217-938-3
meclocyclinum [inn-latin]
7-cloro-6-metilene-5-ossitetraciclina [italian]
meclocycline [usan:inn:ban]
meclociclina [inn-spanish]
meclociclina [italian]
7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide
nsc-78502
meclocycline
gs-2989
2013-58-3
D02476
meclocycline (usan/inn)
CHEBI:135772
CHEMBL1237124
23q8m2he6s ,
unii-23q8m2he6s
7-cloro-6-metilene-5-ossitetraciclina
meclocyclinum
meclociclina
SCHEMBL3445
meclocycline [usan]
meclocycline [mart.]
meclocycline [who-dd]
2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4s-(4a,4a.alpha.,5a,5a.alpha.,12a.alpha.))-
meclocycline [inn]
meclocycline [mi]
SCHEMBL1650332
GGQJXCQBBONZFX-IWVLMIASSA-N
DTXSID4048567
SCHEMBL12841672
AB00053598_03
AB00053598_04
J-013043
SBI-0051646.P002
DB13092
Q6804827
meclocycline-sulfosalicylate
gs 2989;nsc 78502
(4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
SCHEMBL23247761
CS-0013659
HY-B1366A
PD132477

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1566489Inhibition of biotinylated pre-let-7d microRNA (unknown origin) maturation preincubated for 15 mins followed by Pre-let-7d addition and measured after 5 hrs by cat-ELCCA2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1566490Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation at 1 mM measured after 15 mins by cat-ELCCA relative to control2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1566488Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation preincubated for 15 mins followed by pre-miRNA-21 addition and measured after 5 hrs by cat-ELCCA2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1566487Binding affinity to biotinylated pre-let-7d microRNA (unknown origin) by SPR analysis2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1566486Binding affinity to biotinylated pre-miRNA-21 (unknown origin) by SPR analysis2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1566496Binding affinity to miR-21 RNA in human HeLA cells transfected with pmirGLO empty vector incubated for 48 hrs by Dual-Glo luciferase assay2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1566497Binding affinity to miR-21 RNA in human HeLA cells transfected with pmir21 vector incubated for 48 hrs by Dual-Glo luciferase assay2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (64.29)18.7374
1990's1 (7.14)18.2507
2000's2 (14.29)29.6817
2010's2 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.04 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index41.66 (26.88)
Search Engine Supply Index2.67 (0.95)

This Compound (29.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (28.57%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (64.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer [NCT00385515]Phase 281 participants (Actual)Interventional2006-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00385515 (2) [back to overview]Duration of Ulcerative Oral Mucositis
NCT00385515 (2) [back to overview]Number of Participants With Ulcerative Oral Mucositis

Duration of Ulcerative Oral Mucositis

All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to document the duration for those that developed recurrent ulcerative oral mucositis (NCT00385515)
Timeframe: At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle

InterventionDays (Mean)
SNX-10122.3
Placebo3.2

[back to top]

Number of Participants With Ulcerative Oral Mucositis

All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to identify recurrence of ulcerative oral mucositis. (NCT00385515)
Timeframe: At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle

InterventionParticipants (Number)
SNX-101222
Placebo11

[back to top]